Company Active LTD

Company profile

Cis Oncology Limited

CIS Oncology | Experts in Automated Chemotherapy Prescribing

Our ChemoCare system is used by hundreds of NHS trusts across the UK and makes prescribing and patient management quicker, easier and more reliable, using the latest technology for access anywhere, any time.

CRN

02431816

Founded

1989

Age

36

Overview

Legal name

CIS ONCOLOGY LIMITED

Region

South East England

Registered address

FIRST FLOOR, PARK CENTRAL

PARK END STREET

OXFORD

ENGLAND

OX1 1JD

Insolvency history

No

Corporate ownership

Updated 06 Jun 2026 16:52

8 levels 1 ultimate controller

1

Company Active LTD

Cis Oncology Limited

CRN 02431816

2

Direct controller Active LTD

Cis Healthcare Limited

CRN 06001875

3

Intermediate controller Active LTD

System C Healthcare Limited

CRN 01754990

4

Intermediate controller Active LTD

H&Sc Technologies Limited

CRN 09017786

5

Intermediate controller Active LTD

Asclepius Bidco Limited

CRN 13177175

6

Intermediate controller Active LTD

Asclepius Cleanco Limited

CRN 13182955

7

Intermediate controller Active LTD

Asclepius Holdco Limited

CRN 13183040

8

Intermediate controller Active LTD

Asclepius Topco Limited

CRN 13182927

9

Ultimate controller

00140080

CRN 00140080

Company events

Reference milestones and recent Companies House filing stream events.

14 events

31 Oct

2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

31 Mar

2026

Accounts due

Accounts Due

Next accounts due date

17 Oct

2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

12 Nov

2024

Confirmation Statement With Updates

Confirmation-statement

CS01 | Transaction MzQ0Mjc4MjE4OGFkaXF6a2N4

Published 12 Nov 2024 09:47

01 Nov

2024

Termination Director Company With Name Termination Date

Officers

TM01 | Transaction MzQ0MTc0OTE0MmFkaXF6a2N4

Published 01 Nov 2024 12:47

01 Nov

2024

Termination Director Company With Name Termination Date

Officers

TM01 | Transaction MzQ0MTc0OTE0NWFkaXF6a2N4

Published 01 Nov 2024 12:30

01 Nov

2024

Termination Secretary Company With Name Termination Date

Officers

TM02 | Transaction MzQ0MTc0OTA1MGFkaXF6a2N4

Published 01 Nov 2024 12:29

01 Nov

2024

Appoint Person Director Company With Name Date

Officers

AP01 | Transaction MzQ0MTc0ODUyNWFkaXF6a2N4

Published 01 Nov 2024 12:28

01 Nov

2024

Termination Director Company With Name Termination Date

Officers

TM01 | Transaction MzQ0MTc0OTIxN2FkaXF6a2N4

Published 01 Nov 2024 12:20

01 Nov

2024

Appoint Person Director Company With Name Date

Officers

AP01 | Transaction MzQ0MTc0ODI3OGFkaXF6a2N4

Published 01 Nov 2024 12:13

01 Nov

2024

Change Registered Office Address Company With Date Old Address New Address

Address

AD01 | Transaction MzQ0MTc0NjM1MmFkaXF6a2N4

Published 01 Nov 2024 12:00

21 Oct

2024

Accounts With Accounts Type Small

Accounts PDF pending

AA | Transaction MzQ0MDIxOTg5MWFkaXF6a2N4 | Paper/PDF filed

Published 22 Oct 2024 06:23

31 Mar

2024

Accounts filed

Accounts

Last accounts made up date

12 Oct

1989

Incorporated

Inception

Company registered at Companies House

Public funding

1 award

First funded

2011

Funded years

2011

Age at first award

22 years

Projects

2011 Collaborative R&D

Development of a fully integrated service for sequencing-based tumour profiling including data interpretation and commercialisation of assay panel kit products

1 Dec 2011 to 31 Dec 2014

Awarded

£147,319

Total cost £368,482

The aim of this project is to develop a tumour profiling assay based on targeted multiplexed enrichment and next generation sequencing (NGS) of clinically informative genes and variants. Oxford Gene Technology (OGT) will work closely with its partners in Birmingham and Southampton, and the CR-UK Technology hubs to build the assay into an innovative, integ...

Product types

Collaborative R&D